BRIEF-Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results In Western And Asian Patients In Updated Analysis From Global Phase III HARMONi Study

Summit Therapeutics Inc

Summit Therapeutics Inc

SMMT

0.00

July 22 (Reuters) - Summit Therapeutics Inc SMMT.O:

  • IVONESCIMAB PLUS CHEMOTHERAPY SHOWS CONSISTENT, FAVORABLE OVERALL SURVIVAL RESULTS IN WESTERN AND ASIAN PATIENTS IN UPDATED ANALYSIS FROM GLOBAL PHASE III HARMONI STUDY

  • SUMMIT THERAPEUTICS - IVONESCIMAB PLUS CHEMOTHERAPY SHOWS POSITIVE OS TREND IN ASIAN AND WESTERN PATIENTS

  • SUMMIT THERAPEUTICS - PHASE III HARMONI STUDY SHOWS STATISTICALLY SIGNIFICANT PFS BENEFIT

  • SUMMIT THERAPEUTICS - IVONESCIMAB CONTINUES TO SHOW ACCEPTABLE SAFETY PROFILE; NO NEW SAFETY SIGNALS

  • SUMMIT THERAPEUTICS - FDA ACCEPTS BLA FOR IVONESCIMAB; PDUFA DATE NOVEMBER 14, 2026

Source text: ID:nBw8kR4BPa

Further company coverage: SMMT.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.